Recombinant Alkaline Phosphatase Prevents Acute on Chronic Liver Failure
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The lipopolysaccharide (LPS)– toll-like receptor-4 (TLR4) pathway plays an important role in liver failure. Recombinant alkaline phosphatase (recAP) deactivates LPS. The aim of this study was to determine whether recAP prevents the progression of acute and acute-on-chronic liver failure (ACLF). Eight groups of rats were studied 4-weeks after sham surgery or bile duct ligation and were injected with saline or LPS to mimic ACLF. Acute liver failure was induced with Galactosamine-LPS and in both models animals were treated with recAP prior to LPS administration. In the ACLF model, the severity of liver dysfunction and brain edema was attenuated by recAP, associated with reduction in cytokines, chemokines, liver cell death, and brain water. The activity of LPS was reduced by recAP. The treatment was not effective in acute liver failure. Hepatic TLR4 expression was reduced by recAP in ACLF but not acute liver failure. Increased sensitivity to endotoxins in cirrhosis is associated with upregulation of hepatic TLR4, which explains susceptibility to development of ACLF whereas acute liver failure is likely due to direct hepatoxicity. RecAP prevents multiple organ injury by reducing receptor expression and is a potential novel treatment option for prevention of ACLF but not acute liver failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bernal, W., & Wendon, J. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1208937 · Cited by 1,169
Cited by
Engelmann, C., Clària, J., Szabo, G., Bosch, J., & Bernardi, M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.01.002 · Cited by 400
Self-citationToll-like receptor 4 is a therapeutic target for prevention and treatment of liver failure
Engelmann, C., Sheikh, M., Sharma, S., Kondo, T., Loeffler-Wirth, H., Zheng, Y. B., Novelli, S., Hall, A., Kerbert, A. J. C., Macnaughtan, J., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.01.011 · Cited by 174
Self-citationDanger signals in liver injury and restoration of homeostasis
Han, H., Desert, R., Das, S., Song, Z., Athavale, D., Ge, X., & Nieto, N. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.033 · Cited by 127
The Potential Role of Cellular Senescence in Non-Alcoholic Fatty Liver Disease
Engelmann, C., & Tacke, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020652 · Cited by 61
Self-citation
Metadata
- Authors
- Engelmann, C., Adebayo, D., Oria, M., De Chiara, F., Novelli, S., Habtesion, A., Davies, N., Andreola, F., & Jalan, R.
- Venue
- Scientific Reports
- Published
- 2020-01-15
- Volume
- 10
- Issue
- 1
- Pages
- 389-389
- ISSN
- 2045-2322 (ISSN-L)
- OpenAlex
- W2998932876
- Cited by
- 41
- References
- 1
- FWCI
- 3.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recombinant Alkaline Phosphatase Prevents Acute on Chronic Liver Failure. https://app.cochat.ai/papers/10.1038/s41598-019-57284-z
- The paper
- Engelmann, C., Adebayo, D., Oria, M., De Chiara, F., Novelli, S., Habtesion, A., Davies, N., Andreola, F., & Jalan, R. (2020). Recombinant Alkaline Phosphatase Prevents Acute on Chronic Liver Failure. Scientific Reports. https://doi.org/10.1038/s41598-019-57284-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.